IDEAYA Biosciences Inc. (IDYA)
| Bid | 17 |
| Market Cap | 1.79B |
| Revenue (ttm) | 7M |
| Net Income (ttm) | -274.48M |
| EPS (ttm) | -3.36 |
| PE Ratio (ttm) | -6.09 |
| Forward PE | -7.1 |
| Analyst | Buy |
| Ask | 20.59 |
| Volume | 591,349 |
| Avg. Volume (20D) | 1,377,720.5 |
| Open | 20.15 |
| Previous Close | 20.13 |
| Day's Range | 19.39 - 20.49 |
| 52-Week Range | 13.45 - 44.42 |
| Beta | 0.51 |
About IDYA
IDEAYA Biosciences, Inc., a synthetic lethality-focused precision medicine oncology company, focuses on the discovery and development of targeted therapeutics for patient populations selected using molecular diagnostics. The company's lead product candidates include IDE397, a methionine adenosyltransferase 2a inhibitor that is in Phase I clinical trial for patients with solid tumors having methylthioadenosine phosphorylase deletions; and IDE196, ...
Analyst Forecast
According to 13 analyst ratings, the average rating for IDYA stock is "Buy." The 12-month stock price forecast is $53, which is an increase of 158.92% from the latest price.
Stock ForecastsNext Earnings Release
Analysts project revenue of ... Unlock content with Pro Subscription
2 months ago · seekingalpha.com
Ideaya Biosciences: Potential Registration-Enabling Darovasertib Study ComingIdeaya Biosciences, Inc.'s darovasertib + crizotinib combination is being explored in the potential registration-enabling phase 2/3 study targeting patients with 1st-line HLA-A2-negative metastatic uv...
